Recently, relying on the National Protein Science Research (Shanghai) facility, the research team of Tianjin Pharmaceutical Research Institute combined with the traditional Chinese medicine theory of Shufeng Jiedu Capsules, screened and identified 96 main compound components and potential 10 anti-inflammatory active substances in Shufeng Jiedu Capsules , And through the analysis method of multi-level traditional Chinese medicine compound combined with quantitative proteomics technology, revealed the potential molecular mechanism of Shufeng Jiedu capsule in the treatment of acute lung injury in rat models. The analysis process of the pharmacological effects of Shufeng Jiedu Capsules in this study provides a brand-new concept and standard for the analysis of traditional Chinese medicine compound prescriptions, and can be used as one of the landmark studies in the development of follow-up traditional Chinese medicine research methods.
The National Protein Science Research (Shanghai) facility is a major national scientific and technological infrastructure approved by the National Development and Reform Commission. This facility is the first comprehensive large-scale scientific installation in the field of life sciences in the world today, and is an important part of the Shanghai Science and Technology Innovation Center and the Zhangjiang Comprehensive National Science Center.
Relying on the platforms of the Institute of Chinese Materia Medica of the Chinese Academy of Chinese Medical Sciences and the Tianjin Institute of Materia Medica, Jiren Pharmaceutical Group has carried out basic pharmacological and pharmacodynamic research and post-marketing clinical re-evaluation work for the company’s exclusive innovative Chinese medicine Shufeng Jiedu Capsules, determined to promote ethnic medicine, Build a national brand and promote the development of my country's traditional Chinese medicine industry.
Shufeng Jiedu Capsule is a national medical insurance category A variety, and has successively won the first prize of the Science and Technology Award of the Chinese Society of Traditional Chinese Medicine and the National Patent Gold Award. In June 2017, the basic research of Shufeng Jiedu Capsules in the "Fifth International Conference on Influenza and Other Respiratory Virus Diseases-Antiviral Group Meeting" won the only Gilead Award in the field of traditional medicine at this conference.
Jiren Pharmaceutical Group has always adhered to scientific and technological innovation. In 2012, it established a post-doctoral scientific research workstation, and in 2013 it established a corporate academician workstation. It was awarded the Special Contribution Award for Promoting the Academic Development of Chinese Medicine by the Chinese Society of Chinese Medicine. The company's product Shufeng Jiedu Capsules related research papers have been included in 8 foreign SCI, with a cumulative impact factor of more than 20 points. In the National Natural Science Foundation of China announced in 2017, the study on the mechanism of action of Shufeng Jiedu capsules, the exploration of target points, and the study of in vivo processes have been funded by 4 National Natural Science Foundation of China in 2018, through multi-level traditional Chinese medicine. Combining a series of innovative researches such as quantitative proteomics technology with the analytical methods of the company, the establishment of modern Chinese medicine research and innovation methods in line with the characteristics of Chinese medicine will help promote the international development of Chinese national medicine.